Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | LCAT | P04180 | 3/20 | 0.47 |
| ▸ | ACACB | O00763 | 6/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16769742 | 0.89 | LCAT (0.47) | HRH3LCATACACBGPR119KDM4E | |
| SCHEMBL16648490 | 0.84 | USP30 (0.52) | GPR119KDM4E | |
| SCHEMBL1245496 | 0.84 | LRRK2 (0.54) | HRH3LCATACACBGPR119LRRK2 | |
| SCHEMBL16769757 | 0.81 | CHRM4 (0.55) | HRH3LCATACACBKDM4EABL1 | |
| SCHEMBL16769751 | 0.80 | ACACB (0.49) | HRH3LCATACACBKDM4EABL1 | |
| SCHEMBL20152892 | 0.78 | HRH3 (0.53) | HRH3LCATGPR119KDM4EABL1 | |
| SCHEMBL16769734 | 0.78 | HRH3 (0.48) | HRH3LCATACACBKDM4ELMNA | |
| SCHEMBL16769732 | 0.77 | GPR119 (0.53) | GPR119KDM4EABL1LMNA | |
| SCHEMBL16769733 | 0.77 | HRH3 (0.55) | HRH3GPR119KDM4EABL1LMNA | |
| SCHEMBL16769756 | 0.75 | LMNA (0.46) | HRH3LCATGPR119KDM4EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796709-B2 | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20160376267-A1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376267-A1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | LDLR, LCAT, LPL | HRH3 943/4885LCAT 2/4885ACACB 435/4885 |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | LCAT, LPL, LCLAT1 | HRH3 3681/4885LCAT 1/4885ACACB 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.